ESH-ESC guidelines for the management of hypertension

Herz

Volumn 31, Issue 4, 2006, Pages 331-338

  Erdine, Serap ^a   Ari, Oben ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Blood pressure; Guidelines; Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANAMNESIS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; KIDNEY INJURY; LIFESTYLE; MEDICAL SOCIETY; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOLOGY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIASTOLE; DIET; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EUROPE; EXERCISE; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SOCIETIES, MEDICAL; SYSTOLE;

EID: 33745911315     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2829-3     Document Type: Review

References (43)

1. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
2. Parati G, Pomidossi G, Casadei V, et al. Lack of alerting reactions and pressor responses to intermittent cuff inflations during non-invasive blood pressure monitoring. Hypertension 1985;7:597-601.
3. Mancia G, Omboni S, Parati G, et al. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995;8:311-5.
4. Coats AJS, Radaelli A, Clark SJ, et al. The influence of ambulatory blood pressure monitoring. The design and interpretation of trials in hypertension. J Hypertens 1992;10:385-91.
5. Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA Study. J Hypertens 1995;13:1377-90.
6. Pickering T, James GD, Boddie C, et al. How common is white coat hypertension? JAMA 1988;259:225-8.
7. Parati G, Ulian L, Santucci C, et al. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 1998;31:1185-9.
8. Pickering TG, Coats A, Mallion JM, et al. Task Force V. White-coat hypertension. Blood Press Monit 1999;4:333-41.
9. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000;36:894-900.
10. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment induced regression of left ventricular hypertrophy. Circulation 1997;95:1464-70.
11. Imai Y, Ohkubo T, Sakuma M, et al. Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, Northern Japan. Blood Press Monit 1996;1:251-4.
12. Zarnke KB, Feagan BG, Mahon JL, et al. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. Am J Hypertens 1997;10:58-67.
13. Phillips JL, McClellan MW, Pezzullo JC, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000;85:4526-33.
14. Orth DN. Cushing's syndrome. N Engl J Med 1995;332:791-803.
15. Nieman LK. Diagnostic tests for Cushing's syndrome. Ann N Y Acad Sci 2002;970:112-8.
16. Cuspidi C, Macca G, Salerno M, et al. Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examination? Ital Heart J 2001;2:702-6.
17. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997;29:22-9.
18. Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980;93:817-21.
19. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.
20. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981;63:1391-8.
21. Cuspidi C, Ambrosioni E, Mancia G, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002;20:1307-14.
22. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
23. Ciulla M, Paliotti R, Hess DB, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997;10:657-64.
24. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
25. Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: the ARIC Study. Stroke 1996;27:2262-70.
26. Zanchetti A, Mancia G. Editor's Corner. New year, new challenges. J Hypertens 2003;21:1-2.
27. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control. Results from the Health Survey for England 1998. Hypertension 2001;38:827-32.
28. Zanchetti A. Antihypertensive therapy. How to evaluate the benefits. Am J Cardiol 1997;79:3-8.
29. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999;282:539-46.
30. Franklin S, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-9.
31. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2001;37:1042-8.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS38. BMJ 1998;317:703-13.
33. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993;2:962-7.
34. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and 2 diabetes. J Intern Med 2003;254:45-66.
35. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002;20:353-5.
36. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
37. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
38. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001;12:218-25.
39. Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000;35:898-903.
40. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002;39:735-8.
41. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
42. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001;19:2063-70.
43. Campos C, Segura J, Rodicio JL. Investigations in secondary hypertension: renal disease. In: Zanchetti A, Hansson L, Rodicio JL, eds. Hypertension. London: McGraw Hill International, 2001:119-26.